Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 12, 2002, Pages 4-9

  Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; NAVELBINE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING; VOMITING;

EID: 0036333477     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)90001-1     Document Type: Review

References (37)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer
3. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer
4. Phase II trials of Taxotere with non-small cell lung cancer
5. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial
6. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC
7. 2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)
8. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
9. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent
10. Docetaxel and carboplatin for advanced non-small cell lung cancer: Dose of carboplatin influences outcome
11. Docetaxel in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management
12. Phase I/II study of cisplatin and docetaxel in non-small cell lung cancer
13. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer
14. Phase I/II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small cell lung cancer
15. Phase I/II study of docetaxel and carboplatin as Ist line chemotherapy in advanced non-small cell lung cancer. Preliminary results
16. Use of docetaxel and carboplatin for patients with non-small cell lung cancer
17. Docetaxel (Taxotere) plus cisplatin: An active alternative and well tolerated combination in patients with advanced non-small cell lung cancer
18. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer
19. Multicenter phase II study of docetaxel and cisplatin combination in patients with non-small cell lung cancer
20. Phase II study of docetaxel plus cisplatin in a circadian timing as first line chemotherapy in advanced non-small cell lung cancer
21. Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small cell lung cancer: Preserving the efficacy with lower dose regimens
22. Interim analysis of a phase II study of docetaxel (Taxotere) in combination with cisplatin in Korean patients with metastatic (stage IV) or unresected (stage IIIB) localized non-small cell lung cancer
23. First line treatment of advanced 2non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
24. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer
25. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: Results and future developments
26. Docetaxel (Taxotere) and carboplatin in the treatment of advanced non-small cell lung cancer
27. Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer
28. Outpatient Taxotere/carboplatin (T/C) combination therapy in NSCLC for induction in stage IIIB and palliation in stage IV
29. Phase II trial of docetaxel and carboplatin in advanced non-small cell lung cancer
30. Docetaxel/carboplatin combination therapy for stage IlIB/IV non-small cell lung cancer
31. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
32. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
33. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group study
34. Paclitaxel and docetaxel combinations in non-small cell lung cancer
35. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
36. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
37. Preliminary results of a randomized phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and P in stage IV non-small cell lung cancer (NSCLC)